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Abstract
Monitoring genetic diversity and drug resistance mutations (DRMs) is critical for understand-
ing HIV epidemiology. Here, we report HIV-1 genetic diversity and DRMs in blood samples
from 42 HIV-positive pregnant women naive to antiretroviral therapy (ART), in Luanda. The
samples were subjected to nested-PCR, followed by sequencing of HIV-1 pol gene, target-
ing the protease and reverse transcriptase fragments. HIV-1 diversity was analyzed using
the REGA HIV-1 subtyping tool and DRMs were identified using the Calibrated Population
Resistance tool. A total of 34 sequences were obtained. The data revealed wide HIV-1 sub-
types heterogeneity, with subtype C (38%, 13/34) the most frequent, followed by the sub-
types F1 (18%, 6/34), A1 (9%, 3/34), G (9%, 3/34), D (6%, 2/34) and H (3%, 1/34). In
addition, recombinants strains were detected, with CRF02_AG (6%, 2/34) the most fre-
quent, followed by CRF37_cpx, F1/C, A1/G and H/G, all with 3% (1/34). A total of 6/34
(18%) of the sequences presented DRMs. The non-nucleoside reverse transcriptase inhibi-
tors presented 15% (5/34) of resistance. Moreover, 1/34 (3%) sequence presented resis-
tance against both non-nucleoside reverse transcriptase inhibitors and nucleoside reverse
transcriptase inhibitors, simultaneously. Despite the small sample size, our results suggest
the need to update currently used ART regimens. Surveillance of HIV-1 subtypes and
DRMs are necessary to understand HIV epidemiology and to guide modification of ART
guidelines in Angola.
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Introduction
The human immunodeficiency virus (HIV) has become a major global public health problem
[1], affecting about 36.9 million people in the world [2]. In Angola, a total of 310,000 cases
were reported in 2018 [2]. HIV is classified into types (HIV-1 and HIV-2), groups (M, N, O
and P), subtypes (A-D, F-H, J and K), sub-subtypes (A1, A2, F1 and F2), circulating recombi-
nant forms (CRFs) and unique recombinant forms (URFs) [3]. HIV-1 is responsible for the
vast majority of HIV infections [4]. All subtypes of HIV-1 group M (except B), several CRFs
and URFs have been described in Angola [5–11].
Universal access to antiretroviral therapy (ART) has successfully decreased mortality and
morbidity associated with HIV [2,12]. The first-line of the ART drugs used in Angola includes
the nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir (TDF) and lamivudine
(3TC), and a non-nucleoside reverse transcriptase inhibitor (NNRTI), either efavirenz (EFV)
or nevirapine (NVP) [13,14]. In addition, zidovudine (AZT) has been used to prevent vertical
transmission [13,14].
The emergence of HIV-1 subtypes with drug resistance mutations (DRMs) during preg-
nancy represents a challenge for the efficacy of ART, especially in low- and middle-income
countries [15]. There is a lack of recent data on HIV-1 genetic diversity and prevalence of
DRMs in Angola [15,16]. In this study, we investigated the genetic diversity and DRM preva-
lence in blood samples from HIV-positive pregnant women naive to ART in Luanda, to better
understand HIV epidemiology and to allow a timely modification of ART guidelines in
Angola.
Materials and methods
Study design and sample collection
A cross-sectional study was carried out at the Lucrecia Paim Maternity clinic, located in
Luanda, capital city of Angola, during the months of April to June of 2018. The study involved
1612 pregnant women who were screened for HIV infection using the rapid antibody detec-
tion test Determine HIV1/2™ (Alere, Japan) and the Unigold™ HIV (Trinity Biotech, Ireland)
during prenatal care. Sociodemographic characteristics and blood samples were collected from
HIV-positive pregnant women. The main criterion for inclusion of HIV-positive pregnant
women was that they had not been previously exposed to any ART. The blood samples were
collected in a tube with EDTA, centrifuged and the plasma was aliquoted and stored at -80˚C.
The blood samples preparation was performed at the Molecular Biology Laboratory, of the
National Institute for Health Research of Angola (INIS). Following the recommendations of
the National Institute of Fighting against AIDS (INLS), the HIV-positive women, were pre-
scribed ART with TDF, 3TC and EFV, and were medicated with AZT until child birth [13,14].
RNA extraction, cDNA synthesis, PCR and sequencing
Total viral RNA was extracted from 140μL of plasma using QIAamp Viral RNA kit (QIAGEN,
Germany) following the manufacturer instructions. The cDNA synthesis was carried out using
10μL of the RNA in a final reaction volume of 20μL. The mix contained 25mM DNTP mix,
5X M-MLV buffer, 10mM of dithiothreitol (DTT), 40U of RNase OUT™ (Life Technologies,
USA), 0.1mM of MMRTR6 primer (5’-TTTTACATCATTAGTGTGGG-3’), and 200U of
M-MLV enzyme (Life Technologies, USA) [17].
The obtained cDNA was subjected to a nested-PCR, targeting the protease (PR) and reverse
transcriptase (RT) fragments of the HIV-1 pol gene, with an expected size of 1302 bp, using
the protocol previously described [17]. Successful amplification was checked using a 1%
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agarose gel. The amplicons were purified using the NZYGelpure Kit (Nzytech, Portugal), and
sequenced using the ABI BigDye Terminator v3.1 reaction kit (Applied Biosystems, USA). For
each sample, eight primers were used for the complete sequencing of the PR (nucleotide range:
2253–2549) and the first 335 codons of RT (nucleotide range: 2550–3554), considering the
genome of the HXB2 strain (nucleotide range: 2252–3554) [17]. Sequencing was performed on
an ABI 3500 sequencer (Applied Biosystems, USA) at the Molecular Biology Laboratory of the
INIS, in Luanda.
HIV-1 subtyping, phylogenetic and resistance mutation analysis
The electropherograms were analyzed using the software RECALL v2.25 [18]. Classification of
HIV subtypes was conducted using the REGA HIV-1 subtyping tool v3.0 (http://dbpartners.
stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/) [19]. The nucleotide sequences
obtained were aligned with HIV-1 M-group nucleotide sequences downloaded from NCBI
(https://www.ncbi.nlm.nih.gov/nuccore/) and Los Alamos (https://www.hiv.lanl.gov/content/
index) databases. The sequences obtained in the study were deposited in GenBank (NCBI) and
were assigned the accession numbers MK543512 to MK543545. A phylogenetic tree was
inferred using the Neighbor-Joining (NJ) method [20], with Tamura-Nei genetic distances
[21]. Clade support was assessed using 1000 bootstrapped replicates [22]. The phylogeny was
estimated using MEGA software v7.0 [23], and recombinant viruses were characterized by
boot scanning using SimPlot [24].
Drug resistance mutations to HIV-1 were identified using the Calibrated Population Resis-
tance tool (CPR) v8.0 (https://hivdb.stanford.edu/cpr/form/PRRT/) [25]. Additionally, analy-
ses of drug resistance profile were performed using the Stanford genotypic resistance
interpretation algorithm (https://hivdb.stanford.edu/hivseq/by-sequences/) [26].
Statistical analysis
Chi-square (X2) tests were performed to evaluate the association between sociodemographic
characteristics and HIV prevalence at 5% statistical significance in the SPSS v25 statistical pro-
gram (IBM SPSS Statistics, USA).
Ethical considerations
The pregnant women were informed of the study and consented (oral and written) to partici-
pation and follow-up until delivery. Consent from parents or guardians of the minors (under
15 years) was also obtained. All pregnant women underwent pre- and post-test counseling
individually. The HIV study results were provided to the clinical staff to ensure appropriate
patient clinical management. The study protocol was reviewed and approved by the National
Ethics Committee of Angola (nr.13/2018), general directorate from Lucrecia Paim Maternity
clinic (nr.083/GDG/MLP/2018) and the Ethics Research Committee of the NOVA Medical
School/Faculdade de Ciências Me´dicas—Universidade NOVA de Lisboa (nr.51/2019/
CEFCM).
Results
Sociodemographic characteristics
From the 1612 pregnant women tested for HIV, 42 (2.6%) tested positive and not been
exposed to any ART previously. All pregnant women were from Luanda province. A total of
25/42 HIV-positive pregnant women were in the age group of 25–34 years, 18/42 had basic
and secondary education, respectively, and 19/42 were unemployed. Moreover, a total of 12/42
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pregnant women were in the second trimester of gestation, followed by 11/42 in the third tri-
mester and 10/42 pregnant women diagnosed and the sample was obtained just before labor
(Table 1).
Genetic diversity analysis
From the 42 plasma samples subjected to nested-PCR, a total of 34 amplicons and respective
sequences were obtained. It was not possible to obtain amplicons from the remaining 8 sam-
ples, even after repeated PCR attempts using different primers. The genotyping analysis
revealed that 28/34 sequences were HIV-1 pure subtypes and 6/34 recombinants strains. From
the detected pure subtypes, subtype C (38%, 13/34) was the most frequent HIV-1 subtype, fol-
lowed by the subtypes F1 (18%, 6/34), A1 (9%, 3/34), G (9%, 3/34), D (6%, 2/34) and H (3%, 1/
34). From the recombinants strains detected, CRF02_AG (6%, 2/34), was marginally more fre-
quent, followed by CRF37_cpx, F1/C, A1/G and H/G, all with 3% (1/34) (Fig 1).
Table 1. Sociodemographic characteristics of pregnant women tested for HIV in Luanda, Angola, 2018.
Characteristics Pregnant tested HIV prevalence X2 P-Value
Negative Positive
Age group (years)
<15 5/1612 4 (80.0%) 1 (20.0%) 11.985 0.017a
15–24 610/1612 602 (98.7%) 8 (1.3%)
25–34 750/1612 725 (96.7%) 25 (3.3%)
35–44 246/1612 238 (96.7%) 8 (3.3%)
>44 1/1612 1 (100%) 0 (0.0%)
Residence (Municipality)
Luanda 643/1612 623 (96.9%) 20 (3.1%) 7.049 0.424
Viana 408/1612 400 (98.0%) 8 (2.0%)
Belas 188/1612 181 (96.3%) 7 (3.7%)
Kilamba Kiaxi 222/1612 216 (97.3%) 6 (2.7%)
Sambizanga 14/1612 13 (92.9%) 1 (7.1%)
Cazenga 108/1612 108 (100.0%) 0 (0.0%)
Cacuaco 26/1612 26 (100.0%) 0 (0.0%)
Icoli Bengo 3/1612 3 (100.0%) 0 (0.0%)
Level of education
Illiterate 72/1612 72 (100.0%) 0 (0.0%) 2.650 0.449
Basic 616/1612 598 (97.1%) 18 (2.9%)
Secundary 633/1612 615 (97.2%) 18 (2.8%)
Higher 291/1612 285 (97.9%) 6 (2.1%)
Occupation
Unemployed 733/1612 714 (97.4%) 19 (2.6%) 1.124 0.570
Worker 478/1612 463 (96.9%) 15 (3.1%)
Student 401/1612 393 (98.0%) 8 (2.0%)
Gestational Age (trimester)
First 102/1612 93 (91.2%) 9 (8.8%) 33.526 0.000a
Second 176/1612 164 (93.2%) 12 (6.8%)
Third 645/1612 634 (98.3%) 11 (1.7%)
Parturientb 689/1612 679 (98.5%) 10 (1.5%)
a Chi-square (X2) statistics are significant (P<0.05).
b Pregnant woman tested for HIV just before labor.
https://doi.org/10.1371/journal.pone.0225251.t001
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Fig 1. HIV-1 diversity among infected pregnant women in Luanda, Angola, 2018. The analysis involved 34
nucleotide sequences. (A) Frequency of HIV-1 subtypes and recombinants. (B) Recombinants distribution. The
subtypes were identified by the REGA v3.0, and recombinants strains by SimPlot.
https://doi.org/10.1371/journal.pone.0225251.g001
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Genetic distance analysis showed genetic similarity (more than 70%) of HIV-1 subtype C
isolates with isolated from Botswana, Mozambique, Tanzania, South Africa and India. The
subtype F1 was more similar to isolates from Brazil and Spain. The subtype A1 was most simi-
lar to isolates from Cameroon, South Africa, and Pakistan. The subtype G was most similar to
isolates from Portugal, and subtype D, subtype H, and recombinant strain H/G to isolates
from Democratic Republic of Congo. The recombinants strains A1/G, CRF02_AG, and
CRF37_cpx were similar to isolates from Cameroon and Ivory Coast (Fig 2).
Antiretroviral resistance mutations and resistance profile
The sequence analysis showed that 6/34 (18%) of the sequences presented DRMs. Of these, 5/
34 (15%) sequences presented resistance to specific NNRTIs. Moreover, 1/34 (3%) sequence
presented resistance against both NNRTIs and NRTIs, simultaneously. Mutations at positions
K103N (2/34), G190A (2/34), Y181I (1/34), and P225H (1/34) were observed against the class
of NNRTIs, whereas mutations at positions M41L, D67N, T69D and T215S were observed
against NRTIs. A non-polymorphic protease inhibitor (PI) selected mutation was observed at
Fig 2. Evolutionary relationships of HIV-1 subtypes among infected pregnant women in Luanda, Angola, 2018. The analysis
involved 56 nucleotide sequences. All HIV-1 strains identified in this study were from M-group. The phylogenetic tree was inferred
using the NJ method, and Tamura-Nei genetic distances with 1000 bootstrap replicates. Analyses were conducted in MEGA v7.0.
Bootstrap values more than 70% and recombinants strains are indicated.
https://doi.org/10.1371/journal.pone.0225251.g002
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position I85V. High levels of drug resistance were observed for NVP (5/34) and EFV (2/34),
intermediate resistance for EFV (3/34) and AZT (1/34) and low resistance for Abacavir (ABC)
(1/34) and TDF (1/34). In addition, the susceptibility profile associated to the second genera-
tion of NNRTIs was also identified and 1/34 and 3/34 sequence presented high- and low-resis-
tance to Etravirine (ETR) and Rilpivirine (RPV), respectively (Table 2).
Discussion
This study presents an important update on molecular epidemiology of circulating HIV-1
strains in Luanda. The HIV prevalence was 2.6% (42/1612). A significant difference in HIV
positivity was observed between pregnant women of different age groups and pregnancy stage
(P<0.05). On the other hand, residence, level of education and occupation did not show signif-
icant differences (P>0.05) (Table 1).
Genetic analysis of 34 isolates revealed a wide diversity of HIV-1 strains (Fig 1), similar to
that observed in previous studies performed in Angola [5–11]. Though it is hard to prove sta-
tistical significance with our small sample size, our study indicates an increase in HIV-1 sub-
type C, but a slight decrease in subtype F1 in Luanda [5,8]. The genetic similarity of HIV-1
subtype C with isolates from Botswana, Mozambique, Tanzania, South Africa, India and the
subtype F1 with isolates from Brazil and Spain (Fig 2), may be attributed to high mobility
between countries or to the fact that, after colonial war, and the end of civil war in 2002, thou-
sands of refugees returned to Angola [27].
The RT inhibitors are important components of ART regimen [12–14]. The identification
of pre-treatment drug resistance in pregnant women naïve to ART (Table 2), may threaten
ART based strategy to HIV control in Luanda [12–14]. The K103N and G190A mutations
are associated with EFV and NVP resistance [28]. The Y181I and P225H mutations are often
associated with second generation RPV and ETR resistance [29]. The thymidine analogue
associated mutations (TAMs) at positions M41L and D67N have the greatest impact on sus-
ceptibility of AZT and Stavudine (d4T) [28]. The T69D mutation when present with T215S
mutation, is associated with broad resistance to NRTIs [28]. The non-polymorphic PI-selected
mutation at position I85V has minimal effects on PIs susceptibility [30,31].
The identification of K103N and G190A mutations, may be attributed to the long use of
NNRTIs as part of the first-line ART regimens in Angola [13,14]. Displacement of people to
countries where ART is available for a longer period also may help to explain the origin of the
HIV-1 subtypes with DRMs in Luanda [27,32].
The reasons for PCR failure of 8/42 samples were not identified. It may be that the high
HIV-1 genetic diversity compromised the binding of primers, even though they were targeted
at highly conserved regions of the HIV-1. Other studies with more representative sampling
Table 2. Drug resistance mutations to NRTI, NNRTI and PI according to the HIV-1 subtypes and resistance profile.
Isolate HIV-1 subtypes Drug resistant mutations Drug resistance profile
NRTI NNRTI PI Low Intermediate High
P10 A1/G - G190A - ETR, RPV EFV NVP
P12 F1 - K103N, P225H - ETR, RPV - EFV, NVP
P26 H - G190A - ETR, RPV EFV NVP
P27 G M41L, D67N, T69D, T215S Y181I - ABC, TDF AZT, EFV ETR, RPV, NVP
P31 G - - I85V - - -
P41 C - K103N - - - EFV, NVP
Antiretroviral drugs: AZT—Zidovudine; EFV—Efavirenz; ETR—Etravirine; NVP—Nevirapine; RPV—Rilpivirine; ABC—Abacavir; TDF—Tenofovir.
https://doi.org/10.1371/journal.pone.0225251.t002
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monitoring of the HIV-1 subtypes and DRMs are necessary to guide a timely modification of
ART guidelines in Angola. Despite the small sample size, our findings suggest that the Angolan
Ministry of Health should prompt consideration of moving to generic integrase strand transfer
inhibitors (INSTIs) in the ART regimen in Angola [33].
Conclusions
Our results show a wide HIV-1 subtypes heterogeneity, with subtype C the most frequent. A
total of 6/34 (18%) of the sequences presented DRMs. Of these, 15% (5/34) were associated
with resistance against NNRTIs. Moreover, 1/34 (3%) sequence presented resistance against
both NNRTIs and NRTIs, simultaneously. Our findings suggest the need to update currently
used ART regimens. Better understanding is needed of emergence of HIV-1 subtypes and
DRMs, to allow a timely modification of ART guidelines in Angola.
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